ALLMedicine™ Vitiligo Center
Research & Reviews 1,842 results
https://emedicine.medscape.com/article/2111163-print
Jul 1st, 2022 - Background Electrocautery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to ac...
https://emedicine.medscape.com/article/2111163-overview
Jul 1st, 2022 - Background Electrocautery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to ac...
http://emedicine.medscape.com/article/2111163-overview
Jul 1st, 2022 - Background Electrocautery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to ac...
https://clinicaltrials.gov/ct2/show/NCT03076554
Jul 1st, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...
https://clinicaltrials.gov/ct2/show/NCT04811131
Jul 1st, 2022 - This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo.
Guidelines 1 results
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.
Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...
Drugs 6 results see all →
Clinicaltrials.gov 191 results
https://clinicaltrials.gov/ct2/show/NCT03076554
Jul 1st, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...
https://clinicaltrials.gov/ct2/show/NCT04811131
Jul 1st, 2022 - This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo.
https://clinicaltrials.gov/ct2/show/NCT03270241
Jun 30th, 2022 - This is a dermatology study of the effects of short-term NB-UVB treatment, standard phototherapy for Vitiligo patients. In the study, demographics information, three ascending dose of phototherapy, and small skin biopsies will be required of the p...
https://clinicaltrials.gov/ct2/show/NCT04530344
Jun 27th, 2022 - The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed eit...
https://clinicaltrials.gov/ct2/show/NCT04487860
Jun 27th, 2022 - This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study. I
News 242 results
https://www.mdedge.com/dermatology/article/255409/pigmentation-disorders/assessing-treatment-delays-vitiligo-patients
Kavina Patel, MD, Fabiana C.P.s. Lopes, MD et. al.
Jun 14th, 2022 - Similar to other dermatologic conditions, barriers to early care in patients with vitiligo can exacerbate health disparities. 1 Delayed treatment of vitiligo is known to hamper successful disease stabilization and repigmentation, as therapies tend.
https://www.mdedge.com/dermatology/article/255226/pigmentation-disorders/pending-further-study-caution-recommended-treating
Doug Brunk
Jun 6th, 2022 - SAN DIEGO – The risk of laser or intense-pulsed light–induced vitiligo from treating vitiligo with either modality appears to be low, but caution is recommended until further studies are carried out. Those are the preliminary conclusions from a sy.
https://www.mdedge.com/dermatology/article/255160/dermatologic-surgery/whats-ahead-laser-assisted-drug-delivery
Doug Brunk
Jun 2nd, 2022 - SAN DIEGO – Twelve years ago, Merete Haedersdal, MD, PhD, and colleagues published data from a swine study, which showed for the first time that the ablative fractional laser can be used to boost the uptake of drugs into the skin. That discovery p.
https://www.medscape.com/viewarticle/971834
Apr 8th, 2022 - BOSTON — Patients with vitiligo treated with a topical formulation of the Janus kinase (JAK) inhibitor ruxolitinib had significant repigmentation after 1 year on the therapy, reported investigators from two randomized controlled trials presented a...
https://www.mdedge.com/dermatology/article/252375/atopic-dermatitis/wet-your-whistles-alcohol-induced-flushing-use-topical
Emily C. Milam, MD, David E. Cohen, MD, MPH
Mar 3rd, 2022 - Practice Gap The topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus are US Food and Drug Administration approved for the treatment of atopic dermatitis. 1 In addition, these 2 drugs are utilized off label for many other dermatologic.